The Cancer Prevention and Research Institute of Texas—the second largest publicly-funded granting organization for cancer after NIH—may receive $3 billion more to stay open past its current sunset date in 2023.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
